Jane Street’s Denali Therapeutics DNLI Stock Holding History

Jane Street’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.55M	Buy	80,500 +69,900	+659%	+$1.39M	﹤0.01%	5575
2025 Q4	$175K	Sell	10,600 -13,800	-57%	-$233K	﹤0.01%	9834
2025 Q3	$354K	Sell	24,400 -27,300	-53%	-$392K	﹤0.01%	8581
2025 Q2	$723K	Buy	+51,700	New	+$728K	﹤0.01%	6238
2024 Q4	–	Sell	-16,100	Closed	-$469K	–	9623
2024 Q3	$469K	Sell	16,100 -5,900	-27%	-$146K	﹤0.01%	7300
2024 Q2	$511K	Buy	+22,000	New	+$422K	﹤0.01%	6995
2023 Q4	–	Sell	-20,700	Closed	-$427K	–	9283
2023 Q3	$427K	Buy	20,700 +3,300	+19%	+$83.7K	﹤0.01%	6524
2023 Q2	$513K	Buy	+17,400	New	+$489K	﹤0.01%	6283
2022 Q3	–	Sell	-7,400	Closed	-$218K	–	9831
2022 Q2	$218K	Buy	+7,400	New	+$194K	﹤0.01%	8069
2021 Q1	–	Sell	-7,900	Closed	-$662K	–	9169
2020 Q4	$662K	Buy	+7,900	New	+$478K	﹤0.01%	5320

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street's DNLI Position: Q1 2026 in Review

Jane Street reduced its Denali Therapeutics (DNLI) stake by 25% in Q1 2026, selling an estimated $214K and leaving 32,147 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #7548.

Jane Street first reported a position in DNLI in Q3 2018 and has held it in 25 quarters since. The position peaked at $10.8M in Q3 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Jane Street held 32,147 shares of Denali Therapeutics worth $617K as of Q1 2026.
Jane Street sold 10,775 Denali Therapeutics shares in Q1 2026, an estimated $214K.
Denali Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7548 holding.
Jane Street first reported a position in Denali Therapeutics in Q3 2018 and has held it in 25 quarters since.
Jane Street's Denali Therapeutics position peaked at $10.8M in Q3 2024.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.